This study is currently not recruiting participants.

A Pilot Study to Evaluate if Response to Infliximab or Adalimumab May be Regained with the Addition of an Immunomodulator

Study of Immunomodulator Treatment for Patients with Reduced Response to Anti-TNF Therapy

Not Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to treat patients who have lost response to adalimumab or infliximab with an immunomodulator with the goal of eliminating the circulating antibodies to the anti-TNF and restoring efficacy.

Detailed description of study

The purpose of this study is to treat patients who have lost response to adalimumab or infliximab with an immunomodulator with the goal of eliminating the circulating antibodies to the anti-TNF and restoring efficacy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: inflammatory bowel disease
  • Age: 100 years or below
  • Gender: All

This study investigates the use of an immunomodulator in patients who no longer respond to certain anti-TNF therapies. Anti-TNF therapies are treatments that block tumor necrosis factor, a substance in the body that can cause inflammation and lead to immune system diseases. The goal is to reduce the antibodies that prevent these therapies from working effectively.

Participants in the study will receive an immunomodulator, which is a type of medicine that helps to regulate or normalize the immune system. The study aims to see if this treatment can restore the effectiveness of anti-TNF therapies by eliminating the antibodies that interfere with their action.

  • Who can participate: Eligibility criteria are not specified in the provided information. Participants may include adults with reduced response to anti-TNF therapies.
  • Study details: Participants will receive an immunomodulator treatment. The study will monitor the effects of this treatment on the antibodies that interfere with anti-TNF therapies. An inactive substance that looks like the investigational medicine but does not contain any medicine may be used as a placebo.
Updated on 19 Feb 2024. Study ID: 1502834262

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team